A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients
Article Abstract:
The drug rifabutin may not alter the action of the drug didanosine when both are taken by HIV-infected patients. Rifabutin may be used to prevent Mycobacterium avium complex (MAC) disease in HIV patients with advanced infection. Didanosine is used to treat HIV-infected patients who cannot be treated with zidovudine. Researchers tested the drug interaction of rifabutin and didanosine in 12 symptomatic HIV patients. No drug interaction was found using a dose of didanosine of 167 to 375 milligrams (mg) two times a day and a dose of rifabutin of 300 or 600 mg a day. The combination of the two drugs was found to be safe by laboratory measures.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
Effect of antiretroviral therapy and viral load on the perceived risk of HIV transmission and the need for safer sexual practices
Article Abstract:
Some HIV-infected people believe that they don't need to practice safe sex if they are taking protease inhibitors. Protease inhibitors are used in conjunction with other AIDS drugs and can lower blood levels of the virus to undetectable levels. A survey of 147 HIV-infected people found that almost all believed that safe sex was very important for HIV patients who were not taking any AIDS drugs. However, about 20% believed that the risk of transmitting HIV was much less if HIV patients were taking protease inhibitors. Nineteen percent believed safe sex was not as important.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Impact of Mycobacterium avium complex prophylaxis on the incidence of mycobacterial infections and transfusion-requiring anemia in an HIV-positive population
Article Abstract:
Preventing the spread of Mycobacterium avium complex (MAC) infection in HIV-positive populations can decrease cases of mycobacterial infections and the numbers of anemia patients needing transfusions. Bacterial MAC infections are treated effectively with the drug rifabutin and are an important problem for HIV populations. A 1993 retrospective population study showed a decrease in the both MAC infections and transfused anemia patients among HIV-patients who were treated with rifabutin.
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Pharmacokinetics of simultaneously administered zidovudine and didanosine in HIV-seropositive male patients. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine
- Abstracts: Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus
- Abstracts: The effect of tocolytic use in the management of symptomatic placenta previa. Effect of dual tocolysis on the incidence of severe intraventricular hemorrhage among extremely low-birth-weight infants
- Abstracts: Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients
- Abstracts: The primary prevention of coronary heart disease in women. Adjunctive drug therapy of acute myocardial infarction - evidence from clinical trials